.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals along with metastatic intestinal growths that acquired biomarker-matched treatments based upon flowing growth DNA profiling revealed a greater professional perk than those obtaining unparalleled treatment.